Barry Gross, DO
Family Medicine · Fair Haven, MINPI 1811952294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Indivior Inc.$722
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$636
- AstraZeneca$565
- Alkermes, Inc.$521
- Axsome Therapeutics, Inc.$512
- plus $4K from 30 others
Across 72 payments — averaging $397.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$29K
What the payments were for
- Food & beverage$7,89497%
- Education$2083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,468 |
| Indivior Inc. | 30 | $722 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $636 |
| AstraZeneca | 15 | $565 |
| Alkermes, Inc. | 13 | $521 |
| Axsome Therapeutics, Inc. | 12 | $512 |
| Eisai Inc. | 16 | $414 |
| Novo Nordisk | 11 | $356 |
| Idorsia Pharmaceuticals US Inc | 21 | $347 |
| GSK | 8 | $308 |
| Ironshore Pharmaceuticals Inc. | 6 | $280 |
| Braeburn Inc. | 12 | $261 |
| Supernus Pharmaceuticals, Inc. | 7 | $208 |
| Merck | 4 | $169 |
| Paratek Pharmaceuticals, Inc. | 7 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $142 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $132 |
| Orexo US, Inc. | 7 | $123 |
| Lilly USA, LLC | 8 | $112 |
| Gilead | 4 | $76 |
| USWM, LLC | 5 | $76 |
| Bsn Medical Inc | 1 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Almatica Pharma LLC | 3 | $47 |
| Boehringer Ingelheim | 1 | $41 |
| Fidia Pharma USA Inc. | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 1 | $39 |
| Amgen | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $31 |
| Pfizer | 2 | $31 |
| Bayer | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $11 |
| Medicure Pharma Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,102 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 49 | $72,288 |
| MounjaroTirzepatide | 40 | $53,534 |
| OzempicSemaglutide | 29 | $42,978 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 264 | $36,570 |
| EliquisApixaban | 19 | $25,252 |
| XareltoRivaroxaban | 14 | $19,639 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,904 |
| VraylarCariprazine Hcl | 13 | $17,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,394 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,784 |
| BelsomraSuvorexant | 13 | $6,317 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,485 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $4,808 |
| Buprenorphine Hcl | 48 | $3,026 |
| NovologInsulin Aspart | 14 | $2,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $112 | $125,82289 claims |
| Novo NordiskOzempic, Novolog | $356 | $45,91043 claims |
| PfizerEliquis | $31 | $25,25219 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $308 | $18,87934 claims |
| AbbVieVraylar | $1,468 | $17,04913 claims |
| AstraZenecaBreztri Aerosphere | $565 | $10,78412 claims |
| MerckBelsomra | $169 | $6,31713 claims |
| Indivior Inc.Suboxone | $722 | $4,80813 claims |
| Almatica Pharma LLCSertraline Hcl | $47 | $49453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Fair Haven
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.